Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Standard
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. / Untch, Michael; Fasching, Peter A; Konecny, Gottfried E; Hasmüller, Stephan; Lebeau, Annette; Kreienberg, Rolf; Camara, Oumar; Müller, Volkmar; Andreas, Du Bois; Kühn, Thorsten; Stickeler, Elmar; Harbeck, Nadia; Höss, Cornelia; Kahlert, Steffen; Beck, Thomas; Fett, Werner; Mehta, Keyur M; von Minckwitz, Gunter; Loibl, Sibylle.
in: J CLIN ONCOL, Jahrgang 29, Nr. 25, 25, 2011, S. 3351-3357.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
AU - Untch, Michael
AU - Fasching, Peter A
AU - Konecny, Gottfried E
AU - Hasmüller, Stephan
AU - Lebeau, Annette
AU - Kreienberg, Rolf
AU - Camara, Oumar
AU - Müller, Volkmar
AU - Andreas, Du Bois
AU - Kühn, Thorsten
AU - Stickeler, Elmar
AU - Harbeck, Nadia
AU - Höss, Cornelia
AU - Kahlert, Steffen
AU - Beck, Thomas
AU - Fett, Werner
AU - Mehta, Keyur M
AU - von Minckwitz, Gunter
AU - Loibl, Sibylle
PY - 2011
Y1 - 2011
N2 - To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
AB - To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Prospective Studies
KW - Treatment Outcome
KW - Cohort Studies
KW - Survival Rate
KW - Follow-Up Studies
KW - Chemotherapy, Adjuvant
KW - Remission Induction
KW - Neoplasm Invasiveness
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Cyclophosphamide/administration & dosage
KW - Antibodies, Monoclonal/administration & dosage
KW - Breast Neoplasms/drug therapy/mortality/pathology
KW - Carcinoma, Ductal, Breast/drug therapy/mortality/pathology
KW - Carcinoma, Lobular/drug therapy/mortality/pathology
KW - Epirubicin/administration & dosage
KW - Neoadjuvant Therapy
KW - Paclitaxel/administration & dosage
KW - Receptor, erbB-2/metabolism
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Prospective Studies
KW - Treatment Outcome
KW - Cohort Studies
KW - Survival Rate
KW - Follow-Up Studies
KW - Chemotherapy, Adjuvant
KW - Remission Induction
KW - Neoplasm Invasiveness
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Cyclophosphamide/administration & dosage
KW - Antibodies, Monoclonal/administration & dosage
KW - Breast Neoplasms/drug therapy/mortality/pathology
KW - Carcinoma, Ductal, Breast/drug therapy/mortality/pathology
KW - Carcinoma, Lobular/drug therapy/mortality/pathology
KW - Epirubicin/administration & dosage
KW - Neoadjuvant Therapy
KW - Paclitaxel/administration & dosage
KW - Receptor, erbB-2/metabolism
M3 - SCORING: Journal article
VL - 29
SP - 3351
EP - 3357
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 25
M1 - 25
ER -